What are the payment terms?

Accepted payment methods include LC, T/T, D/P, PayPal, Western Union, and small-amount payment.

ND+Ib Combination Vaccine (Strain La Sota + Strain H52) , Live for Poultry

Name: ND+Ib Combination Vaccine (Strain La Sota + Strain H52) , Live for Poultry
Brand: Henan Muxiang Biological Co., Ltd.
SKU: 1925574991

Henan, ChinaHenan Muxiang Biological Co., Ltd.

US$0.82-1.65

1,000 bottle

Sample price:US$2.00/bottle.Request sample

Product profile

Customization

Available

Varieties

Live Vaccine

Component

Chemical Synthetic Drugs

Model NO.

Type

The First Class

Pharmacodynamic Influential Factors

Animal Species

Storage Method

Prevent High or LowTemperature

Transport Package

Carton

Specification

1000 feathers/bottle; 2000 feathers/bottle

Trademark

Moosun

Origin

China

HS Code

300230000

Production Capacity

100000 Bottles/Month

Key features

Dual Protection Vaccine: Combines La Sota and H52 strains to prevent Newcastle Disease and Infectious Bronchitis.

Flexible Administration: Suitable for nasal dropping or drinking water administration for chickens over 21 days old.

High Capacity Options: Available in 1000 and 2000 doses per bottle to meet varying flock sizes.

OEM/ODM Support: Manufacturer offers OEM and ODM services for customized veterinary solutions.

Established Manufacturer: Factory established in 2004 with 360 employees and advanced production equipment.

Company profile

Henan Muxiang Biological Co., Ltd.

Henan, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 2016-02-01 CertifiedNearest Port: Shanghai Port, Qingdao PortAverage Response Time: ≤15h CertifiedTerms of Payment: LC, T/T, D/P, etc.

AI-Powered supplier vetting

SummaryHenan Muxiang Biological Co., Ltd. is a China-based limited-company factory established in 2004, with 360 employees and operations in veterinary pharmaceuticals and animal-health products. The supplier reports seven pharmaceutical production lines, eight vaccine production lines, first-class production and inspection equipment, GMP management, ISO9001:2015 certification, and ISO/CNAS laboratory certification. Its R&D resources include more than 40 core personnel, over 30 of whom hold doctoral or master's degrees, while 21–30 quality-control staff are reported. The company exports to multiple global regions, has self-operated import and export rights, and states a one-month order-fulfillment period in both peak and off-peak seasons. Evidence supports capabilities in certification, innovation, production, and international operations. However, the provided information does not sufficiently establish after-sales service performance, financial credibility, customization execution, or specific customer cases.

Supplier typeThe supplier is identified as a limited company and a factory in the manufacturing industry, with its operating location in Henan, China. This indicates a direct manufacturing entity rather than only a trading or intermediary business.

CertificationsThe supplier reports a systematic GMP management system, ISO/CNAS laboratory international certification, and an ISO9001:2015 certificate. These stated certifications and quality systems provide explicit evidence of formal quality-management capability.

R&D capabilityThe supplier reports more than 40 core R&D personnel, including over 30 doctors or master's degree graduates, 20 years of preparation-technology experience among R&D engineers, and advanced R&D platforms such as a National Enterprise Technology Center, National Postdoctoral Research Station, and Academician Workstation. It also reports improving herbal active-ingredient extraction by more than 30% versus a traditional process, supporting a strong stated innovation profile.

Production capacityThe supplier reports seven pharmaceutical production lines and eight vaccine production lines, first-class production and inspection equipment, six production lines in a separate operational data field, and one-month order fulfillment in both peak and off-peak seasons. Although the line-count figures are not fully consistent across the slices, the evidence clearly supports substantial pharmaceutical and vaccine manufacturing capability.